

Supporting information for

**Interaction of oxovanadium(IV)-salphen complexes with bovine serum albumin and their cytotoxicity against cancer**

**Velusamy Gomathi Sankareswari<sup>a</sup>, Devaraj Vinod<sup>b</sup>, Ayyasamy Mahalakshmi<sup>c</sup>, Meena Alamelu<sup>d</sup>, Ganesan Kumaresan<sup>d</sup>, Ramasamy Ramaraj<sup>a\*</sup> and Seenivasan Rajagopal<sup>a\*</sup>**

**Table S1.**  $^1\text{H}$ NMR data of the salophen ligands

Ligand	$\delta$ OH	$\delta$ Ar-H	$\delta$ N=CH	$\delta$ CH <sub>3</sub>	$\delta$ OCH <sub>3</sub>
<b>1</b>	13.10(s,2H)	6.90- 7.40(m,12H)	8.64(s,2H)	—	—
<b>2</b>	13.10(s,2H)	6.92- 7.50(m,10H)	8.58(s,2H)	—	—
<b>3</b>	13.15(s,2H)	6.81- 7.51(m,10H)	8.57(s,2H)	—	—
<b>4</b>	13.10(s,2H)	6.99- 7.40(m,10H)	8.57(s,2H)	—	—
<b>5</b>	12.81(s,2H)	6.93- 7.33(m,10H)	8.58(s,2H)	2.30(s,6H)	—
<b>6</b>	12.60(s,2H)	6.89- 7.31(m,10H)	8.60(s,2H)	—	3.80(s,6H)
<b>7</b>	13.50(s,2H)	7.00- 7.91(m,8H)	8.92(s,2H)	—	—
<b>8</b>	13.54(s,2H)	7.21- 7.43(m,8H)	8.66(s,2H)	1.32(s,18H),1.43(s,18H)	—

**Table S2.**  $^{13}\text{C}$  NMR data of ligands

Ligand	$^{13}\text{C}$ NMR
<b>1</b>	117.5,118.9,119.2,119.7,127.6,132.3,142.5,161.3,163.7
<b>2</b>	119.1,119.6,119.9,123.6,128.2,131.2,133.2,142.1,159.8,162.4
<b>3</b>	110.5,119.6,120.6,128.2,134.3,136.1,142.2,160.4,162.4
<b>4</b>	20.3,117.3,118.8,119.7,127.5,128.0,132.2,134.3,142.7,159.1,163.7
<b>5</b>	30.9,56.0,115.3,118.4,119.7,120.8,127.7,142.6,152.2,155.6,163.4
<b>6</b>	29.4,31.4,34.1,35.1,118.3,119.8,126.7,127.2,128.1,137.1,140.3,142.7,158.5,164.7

**Table S3.** EPR data for oxovanadium(IV)-salophen complexes

Complex	$\mathbf{g}_{\text{iso}}$	$\mathbf{g}_{\text{II}}$	$\mathbf{g}_{\text{I}}$	$\mathbf{A}_{\text{II}} \text{ cm}^{-1}$	$\mathbf{A}_{\text{iso}} \text{ cm}^{-1}$
<b>I</b>	1.960	1.976	1.286	$304.5 \times 10^{-4}$	$198.0 \times 10^{-4}$
<b>II</b>	1.960	1.950	1.319	$292.6 \times 10^{-4}$	$195.0 \times 10^{-4}$
<b>VI</b>	1.960	1.977	1.284	$303.2 \times 10^{-4}$	$196.9 \times 10^{-4}$
<b>VIII</b>	1.960	1.950	1.319	$292.6 \times 10^{-4}$	$197.8 \times 10^{-4}$

**Table S4.** IR data of the salophen ligands

Ligand	v(C-OH)	v(C=N)	v(C-N)
<b>1</b>	3054	1614	1344
<b>2</b>	3077	1612	1313
<b>3</b>	3073	1612	1313
<b>4</b>	3085	1617	1297
<b>5</b>	3300	1618	1298
<b>6</b>	3313	1614	1280
<b>7</b>	3058	1614	1294
<b>8</b>	3056	1614	1319

**Table S5.** IR data of the oxovanadium (IV)-salophen complexes

Complex	v(C=N)	v(C-N)	v(C-O)	v(V=O)	v(V-N)	v(V-O)
<b>I</b>	1607	1315	1196	978	542	484
<b>II</b>	1607	1310	1280	970	522	495
<b>III</b>	1605	1306	1246	968	515	443
<b>IV</b>	1618	1340	1298	978	532	419
<b>V</b>	1620	1298	1263	978	536	469
<b>VI</b>	1595	1285	1220	974	540	491
<b>VII</b>	1603	1325	1227	987	540	487
<b>VIII</b>	1601	1313	1250	976	542	484

**Table S6.** Excited-state dynamic ( $K_D$ ) and static ( $K_S$ ) Stern–Volmer constant and quenching rate constants ( $k_q$ ) of BSA with salphen ligands and oxovanadium(IV)–salphen complexes.

Ligand	$1$	$6.4 \times 10^5$	$1.9 \times 10^3$	$1.1 \times 10^{13}$
Ligand	$7$	$2.0 \times 10^4$	$3.2 \times 10^5$	$3.4 \times 10^{12}$
Complex	II	$4.9 \times 10^4$	$1.0 \times 10^4$	$8.3 \times 10^{12}$
Complex	IV	$5.1 \times 10^4$	$1.2 \times 10^4$	$8.7 \times 10^{12}$
Complex	V	$1.1 \times 10^5$	$1.3 \times 10^4$	$1.8 \times 10^{13}$
Complex	VI	$1.0 \times 10^5$	$3.3 \times 10^4$	$1.7 \times 10^{13}$
Complex	VII	$1.6 \times 10^5$	$2.2 \times 10^4$	$2.7 \times 10^{13}$
Complex	VIII	$6.0 \times 10^4$	$1.6 \times 10^4$	$1.0 \times 10^{13}$

**Table S7.** Förster Energy Transfer Parameters (FRET) parameters of salphen ligands and oxovanadium(IV)–salphen complexes with BSA.

Sample	$J$ ( $M^{-1} \text{ cm}^3$ )	$R_0$ (nm)	$r$ (nm)	E
Ligand <b>1</b>	$1.8 \times 10^{-14}$	2.72	2.09	0.72
Ligand <b>2</b>	$1.8 \times 10^{-14}$	2.73	2.75	0.41
Ligand <b>3</b>	$1.3 \times 10^{-14}$	2.61	2.49	0.52
Ligand <b>4</b>	$3.2 \times 10^{-14}$	3.03	3.21	0.38
Ligand <b>5</b>	$2.0 \times 10^{-14}$	2.83	2.78	0.51
Ligand <b>6</b>	$1.7 \times 10^{-14}$	2.74	2.28	0.63
Ligand <b>7</b>	$7.0 \times 10^{-15}$	2.32	2.30	0.50


Complex <b>I</b>	$2.3 \times 10^{-14}$	2.94	2.23	0.69
Complex <b>III</b>	$2.1 \times 10^{-14}$	2.80	2.88	0.34
Complex <b>V</b>	$4.0 \times 10^{-14}$	3.12	2.98	0.61
Complex <b>VI</b>	$3.5 \times 10^{-14}$	3.04	1.39	0.76
Complex <b>VII</b>	$2.3 \times 10^{-14}$	2.82	3.49	0.57

**Table S8.** Circular Dichroism spectral data of BSA with oxovanadium(IV)-salphen complexes.


	<b>μM</b>	<b>λ max</b>	<b>M deg</b>	<b>α-helicity (%)</b>
<b>BSA alone</b>		208	-122.94	59
		222	-112.69	53
<b>Complex</b>				
<b>I</b>	1	208	-99.50	45
	2	208	-71.14	28
<b>II</b>	1	208	-90.22	40
	2	208	-39.84	10
<b>III</b>	1	208	-88.75	38
	2	208	-67.75	26
<b>IV</b>	1	208	-89.71	39
	2	208	-69.16	27
<b>V</b>	1	208	-77.48	32
	2	208	-70.63	28
<b>VI</b>	1	208	-93.16	41
	2	208	-70.18	28
<b>VII</b>	1	208	-106.37	49
	2	208	-69.69	27
<b>VIII</b>	1	208	-94.13	42
	2	208	-69.67	27

**Table S9** The IC<sub>50</sub> values for V(IV) complexes against AGS gastric cell lines.


Complex	IC <sub>50</sub> values (μM)
I	1.2
II	0.4
III	38.7
IV	53.7
V	36.6
VI	0.8
VII	33.2
VIII	38.9




**Fig. S1.** ESI-MS spectrum of Ligand 1.




**Fig. S2.** ESI-MS spectrum of Complex **I**.







**Fig.S3.** Cyclic voltammograms of complexes **I**, **II**, **III**, **V**, **VI**, **VII** and **VIII** at room temperature in  $\text{CH}_3\text{CN}$  with 0.1 M tetrabutylammonium per chlorate as the supporting electrolyte, glassy carbon, platinum wire and  $\text{Ag}/\text{AgCl}$  as working, supporting and reference electrodes respectively, under nitrogen. Scan speed :  $100 \text{ mV s}^{-1}$ .




**Fig. S4.** Hammett plot




**Fig. S5.** UV-visible overlay spectra of a) ligands b) complexes.




**Fig. S6** Absorption spectral changes of BSA (2 $\mu$ M) with the addition of complex I (0–20 $\mu$ M) in 2%CH<sub>3</sub>CN–98%H<sub>2</sub>O (v/v), pH=7.4 at 300 K.




**Fig. S7** Modified Benesi-Hildebrand plot of a)Ligand 1 b) Complex I with BSA.




**Fig. S8** Synchronous fluorescence spectra of BSA (5  $\mu$ M) upon addition of complex I (0–50  $\mu$ M.) a)  $\Delta\lambda = 60$  nm b)  $\Delta\lambda = 15$ nm 2%CH<sub>3</sub>CN–98%H<sub>2</sub>O (v/v), pH=7.4 at 300 K.



**Fig . S9** CD Spectra of BSA ( $2 \times 10^{-6}$  M)a) In the UV region in the absence (1) and in the presence of a) complex I with concentration (2) and (3) b) In the visible region complex I at  $1 \times 10^{-6}$  M (2) ,  $2 \times 10^{-6}$  M (3)  $3 \times 10^{-6}$  M (4) at pH 7.4 and 37° C.



**Fig. S10** The plot shows the overall interaction of our synthesized compounds (y axis) with different amino acid residues (x axis) with respective interaction count / influence of synthesized ligand against amino acid or vice versa as shown in right side of the plot (y axis :count of ligand interactions) and above the plot (x axis :count of residue interactions ).




**Fig.S11** RMSD of the protein backbone against the time scale of 5 ns explicit molecular dynamics simulation.




Latest.mpeg

**Fig.S12** Video clip file for the explicit molecular dynamics of the complex V with BSA.



**Fig.S13** Cell viability of salphen ligands **1** and **8** on AGS gastric cell line *in vitro*.



**Fig.S14** Cytotoxic activity of oxovanadium (IV) complexes against AGS gastric cell lines.